← Back to Clinical Trials
Recruiting NCT03336008

NCT03336008 Hong Kong Spinocerebellar Ataxias Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03336008
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Spinocerebellar Ataxia
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2012-12-07
Primary Completion 2034-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type OBSERVATIONAL
Interventions
no intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2012-12-07 with a primary completion date of 2034-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Spinocerebellar ataxias (SCA) 1, 2, 3 and 6 are the most common, autosomal dominantly inherited cerebellar degenerations. And in the Chinese population, the most common SCA is SCA3 and the frequency of SCA 3 among SCA patients is 72.5%, followed by SCA 2 that the frequency is 12% among SCA patients. For SCA 1, the frequency among SCA patients is 7%. Even SCAs are rare diseases, a significant amount of Chinese in Hong Kong still suffer from this disorders. SCA Association in Hong Kong has 88 members who are suffering from spinocerebellar degeneration, many of them have a genetic confirmation. As there are few treatments for SCAs; therefore, understanding SCAs clinical manifestation and disease mechanisms are the first step towards development of effective treatment. The objective of this study is to develop the first SCA registry in Hong Kong with bio-repository bank for clinical and genetic information as well as serum and fibroblasts.

Eligibility Criteria

Inclusion Criteria: 1. Age 18 years and above 2. Presence of symptoms and signs of ataxia 3. Definite molecular diagnosis of SCA1, 2, 3, 6, 7, 8 or 12 either in the participant or another affected family member 4. Willingness to participate in the study and ability to give informed consent Exclusion Criteria: 1\. Known recessive. X-linked, and mitochondrial ataxias

Contact & Investigator

Central Contact

Anne YY CHAN

✉ yychananne@gmail.com

📞 (852) 3505 1855

Principal Investigator

Anne YY CHAN

PRINCIPAL INVESTIGATOR

Chinese University of Hong Kong

Frequently Asked Questions

Who can join the NCT03336008 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Spinocerebellar Ataxia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03336008 currently recruiting?

Yes, NCT03336008 is actively recruiting participants. Contact the research team at yychananne@gmail.com for enrollment information.

Where is the NCT03336008 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT03336008 clinical trial?

NCT03336008 is sponsored by Chinese University of Hong Kong. The principal investigator is Anne YY CHAN at Chinese University of Hong Kong. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology